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Diabetes is one of the major challenges of modern medi-
cine, as it is considered a global epidemic of the XXI 
century. The disease often leads to the development of 
serious, health threatening complications. Diabetic foot 
syndrome is a characteristic set of anatomical and mo-
lecular changes. At the macroscopic level, major symp-
toms are neuropathy, ischemia and chronic ulceration 
of the lower limb. In every third patient, the neuropathy 
develops into Charcot neuroarthropathy characterized 
by bone and joints deformation. Interestingly, all these 
complications are a result of impaired healing process-
es and are characteristic for diabetes. The specificity of 
these symptoms comes from impaired molecular mecha-
nisms observed in type 1 and type 2 diabetes. Decreased 
wound and fracture healing reflect gene expression, cel-
lular response, cell functioning and general metabolism. 
Here we present a comprehensive literature update on 
the molecular factors contributing to diabetic foot syn-
drome.
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InTRoDuCTIon
Diabetes is one of the most deceitful diseases that af-
fect more than 346 million people in the world (WHO 
organization 2012). Not only is the disease itself dan-
gerous but it leads to many complications, like vascular 
damage and retinopathy (Pirola et al., 2010). The inci-
dence of these complications increases with age and du-
ration of diabetes. Of all diabetic complications, diabetic 
foot is one of the most devastating and costly (Cornell 
& Dorsey, 2012). It develops as a result of neuropathy 
and ischemia. The risk of foot ulceration development 
as a consequence of above pathologies is as high as 25% 
(Singh et al., 2005). 
One of the outcomes of neuropathy is the develop-
ment of insensitive foot, which increases the risk of ul-
ceration. Degeneration of sensory innervation leads to 
insensitivity to pain caused by ulcers, wounds, or in-
fections, which are the major causes of limb loss. Dia-
betic foot syndrome also includes Charcot arthropathy, 
which is a relatively rare complication of diabetes but 
studies report incidence of 0.15% up to nearly 2.5% 
(Gupta & Mohan, 2003; Vasquez & Henderson, 2010). 
It occurs in patients diagnosed with deep damage to 
the peripheral nervous system and intact circulation 
in the feet. It is believed that in the group of patients 
with neuropathy, about 16% may develop neuroar-
thropathy (Cavanagh et al., 1994). Due to the lack of 
specific markers and a non-specific clinical picture of 
Charcot osteoarthropathy, as many as 25% of cases can 
be missed or the diagnosis may be delayed (Frykberg 
& Belczyk, 2008). Late diagnosis and lack of treatment 
may result in irreversible deformity of the foot, which 
is then prone to ulceration, infection and consequently 
may require amputation. Because of the limited treat-
ment availability and serious consequences, diabetic 
foot syndrome is becoming an important issue. In the 
current review, we focused on the molecular basis of 
the diabetic foot syndrome. Our aim was to gather in-
formation about the factors that contribute to chronic 
ulceration and bone degeneration, and their function in 
the context of diabetes.
PATHogenesIs of neuRoPATHy
The mechanism behind the development of the dia-
betic neuropathy is complicated. However, angiopathy 
and hyperglycemia-induced metabolic changes play the 
major role. Long-term hyperglycemia causes metabol-
ic disorders which further lead to activation of addi-
tional glucose metabolism pathways, in particular the 
polyol pathway (Yagihashi et al., 2007). Severe changes 
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in the polyol pathway lead to an increased accumula-
tion of sorbitol in cells of nervous tissue. Sorbitol is 
an intermediate product of the glucose-fructose con-
version. The reaction is catalyzed by the enzyme al-
dose reductase. Initially, glucose is reduced to sorbitol 
and sorbitol is then oxidized to fructose. In hypergly-
cemia, this process is intensified leading to accumula-
tion of sorbitol in axons, followed by cellular water 
influx, swelling and Schwann cell damage (Yagihashi 
et al., 2007; Prashanth et al., 2010). Apart of the direct 
effect on nervous tissue, chronic hyperglycemia is cor-
related with vascular damage (Turner, 1998). Increased 
blood sugar levels may lead to epithelial cell dysfunc-
tion, which results in a decrease of pro-angiogenic 
signaling and production of nitric oxide (NO) (Lusis, 
2000). NO additionally causes relaxation of smooth 
muscle, and its absence decreases vasodilatation, in 
consequence impairing blood supply to the nerve 
(Parashanth et al., 2010). Neuropathy in diabetes is 
correlated with cardiovascular damage not only result-
ing from metabolic defects, but caused by other risk 
factors such as hypertension, hyperlipidemia, obesity 
and cigarette smoking (Tesfaye et al., 2005). Moreover, 
micro and macroangiopathy have been identified as 
risk factors in type 2 diabetes mortality. Interestingly, 
microangiopathy is associated with poor glycemic con-
trol, and can develop as a consequence of hyperglyce-
mia (Forsblom et al., 1998).
PHAses of wounD HeAlIng
The major reason for the limb amputation in diabe-
tes is a high risk of sepsis. Infections develop due to 
chronic, non-healing wounds and ulcers (Bartus et al., 
2004). To date, apart from the general diabetes care, 
the medical treatment of diabetic foot focuses mostly 
on proper wound treatment, with attention to regenera-
tion enhancement, and fighting infections (Lipsky et al., 
2012; Apelqvist, 2012). In the diabetic foot, the wound 
healing process is impaired or inhibited, which results in 
anatomical changes (Lobmann et al., 2005). Non-healing 
wounds may accelerate morbidity and mortality (Xu et 
al., 2012). The wound healing process depends on the 
general health of the patient, the location of the wound, 
age and accompanying diseases such as diabetes (Lob-
mann et al., 2005). The proper wound repair progresses 
through a number of ordered events. It is initiated by 
restoration of 1) hemostasis, followed by clot formation, 
2) inflammation, 3) migration and cell proliferation de-
termined by angiogenesis, granulation, tissue formation, 
epithelization and wound contraction, 4) cutaneous tis-
sue remodeling (Blaktyny et al., 2006; Gethin, 2007; Guo 
& DiPietro, 2010). 
noRmAl wounD HeAlIng PRoCess
In general, wound healing depends on an interplay 
between different cell types and their contact mediat-
ed by soluble chemicals and hormones. In the wound 
site, platelets accumulate and aggregate, subsequently 
producing different growth factors responsible for 
the formation of the clot and matrix. Production of 
thrombin which initiates transformation of fibrinogen 
to fibrin, leads to the formation of a mesh stabilizing 
platelets at the site of injury. In addition, cytokines and 
growth factors permeabilize blood vessels, allowing for 
migration of leukocytes (Blaktyny et al., 2006).The leu-
kocytes are attracted to the injured area by products 
of the decomposition of collagen and elastin, as well 
as cytokines TGF-β, TNF-α, interleukin-1 (IL-1) and 
platelet factor IV (Monaco et al., 2003). Accompany-
ing neutrophils and macrophages remove contaminating 
bacteria and other foreign factors present at the wound 
site. Both neutrophils and macrophages release growth 
factors which initiate the formation of the tissue struc-
ture (platelet derived growth factor-PDGF and vascu-
lar endothelial growth factor-VEGF). Macrophages are 
responsible for releasing angiogenesis factor (AGF), 
which stimulates formation of new blood vessels. The 
processes of cell migration and proliferation are modu-
lated by various factors, including epidermal growth 
factor (EGF) and keratinocyte growth factor (KGF-
also known as FGF). Cell migration may also require 
the secretion of matrix metalloproteinases (MMP). This 
is necessary for partial degradation of the clot and the 
extracellular matrix (ECM) at the wound site. Partial di-
gestion of the extracellular matrix forms space for the 
migrating cells. This process is tightly regulated and a 
balance between degradation and formation of new tis-
sue has to be maintained (Madlener et al., 1998). On 
the other hand, collagen synthesis rebuilds the tissue 
and is stimulated by TGF (transforming growth fac-
tor), PDGF (platelet derived growth factor), and EGF 
(epidermal growth factor). Wound contraction, which is 
the last stage of the healing process, is an effect of the 
activity of mesenchymal cells (Blaktyny et al., 2006).
wounD HeAlIng In DIAbeTes
In diabetes, it has been observed that all stages of 
wound healing are affected in diabetic foot syndrome. 
This leads to a specific picture of diabetic wound, 
which is a hallmark of diabetic foot syndrome. It has 
been shown that a large number of growth factors, 
cytokines and chemokines, which are released by ke-
ratinocytes, fibroblasts, endothelial cells, macrophages 
and platelets, have their serum levels changed in dia-
betes. These factors are responsible for initiating the 
wound repair process and its maintenance, which re-
sults in gradual decrease in inflammatory response (Eu-
bank & Marsh, 2010; Blaktyny et al., 2006). Diabetic 
wounds are characterized by a reduced level of the fol-
lowing growth factors and receptors: KGF (keratino-
cyte growth factor), TGF-β1 (transforming growth fac-
tor beta), NGF (nerve growth factor), PDGF, VEGF, 
IL-8, IL-10, IL-15, neurotrophin-3 (NT-3), substance P, 
CGRP (Blaktyny et al., 2009). Selected factors are de-
scribed in Table 1. Decreased levels of these important 
growth factors might contribute to poor tissue regen-
eration and impaired wound healing.
effeCTs of Tgf-β1 DefICIenCy
Deficiency of TGF-β1 in chronic wounds may con-
tribute to the increased level and activity of nitric ox-
ide synthase (NOS). The enzyme produces nitric oxide 
(NO) which is a signal molecule with biological activity. 
The effects of NO signaling vary in different cell types 
and tissues. In general, it causes relaxation of smooth 
muscle, what leads to increased blood flow in blood 
vessels. However, during wound healing the contraction 
of blood vessel helps to prevent bleeding, thus NO ac-
tion early during healing is unfavorable. Additionally 
its action is associated with prevention of platelet ag-
gregation and leukocyte adhesion (Riddel & Owen, 
1999). It is possible that increased levels of NO in the 
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plasma are associated with recurrent ulcers in diabetic 
foot syndrome (Blaktyny et al., 2006; Stojadinovic et al., 
2012). The synthesis of NO positively correlates with 
expression of heat shock proteins (Hsps), while inhibi-
tion of the process reduces levels of Hsp (Mayshylev et 
al., 1995).
Abnormalities in the functioning of the heat shock 
proteins, which are also observed in diabetes, may lead 
to impairment of wound healing. In contrast to the in-
creased Hsp levels observed in diabetic patients, rats 
with chemically induced diabetes show decreased levels 
of Hsp72 protein in blood. Interestingly, regulation oc-
curs at the protein level since mRNA level is not affect-
ed (Bitar et al., 1999; Yamagishi et al.; 2001, Atalay et al., 
2009). Current model explains the role of Hsp72 by its 
involvement in protein folding as well as in the transport 
of newly synthesized proteins required for tissue recon-
stitution (Kruglikov et al., 2011).
wounD RePAIR THRougH PRoTeolysIs
Cell-to-cell communication is mediated by growth fac-
tors and cytokines secreted to the extracellular matrix 
(ECM). The dynamics of this extracellular environment 
is modulated by matrix metalloproteinases (MMPs) (Mc-
Cawley & Martisan, 2001). These proteolytic enzymes 
are zinc-dependent endopeptidases (Maskos, 2004) Sub-
strates for MMPs include structural elements of ECM 
(collagen, fibronectin, basal membrane), cell membrane 
receptors (CD44, ICAM-1, IGFBP) and growth factors 
precursors (pro-TNFα and precursor of TGFβ) (Nagase 
et al., 2006). Interestingly, mature forms of growth fac-
tors (CTGF and HB-EGF) and cytokines (RANKL and 
IL-1β) can also be substrates (Hao et al., 2003; Hashi-
moto et al., 2002; Zhang et al., 2003). Importantly, prote-
olysis may lead to activation or solubilization by release 
from ECM, as well as to degradation of the substrate 
(Visse & Nagase 2003, Nagase et al., 2006). It has been 
demonstrated that most MMP-encoding genes have a 
TGF-β1-dependent inhibitory element in the promot-
er region, which downregulates the gene’s expression. 
Decreased levels of TGF-β1 lead to overexpression 
of MMPs, which results in excessive digestion of the 
growth factors. However, the molecular details of MMPs 
overexpression in diabetes are still not known (Stojadi-
novic et al., 2012). MMPs activity is modulated by tissue 
inhibitors of metalloproteinases (TIMPs), represented by 
four isoforms (Brew et al., 2000). These inhibitors enable 
tight regulation of protease activity preventing tissue de-
struction. This physiological balance between MMPs and 
their specific TIMPs is disrupted in diabetes (Lobmann 
et al., 2002; Stojadinovic et al., 2012). Several studies have 
shown a high concentration of MMP9 in wound liquid 
and a high ratio of MMP9 to TIMP-1 portends poor 
healing of diabetic foot ulcers (Ladwig et al., 2002; Liu 
et al., 2009). 
The aspartic endopeptidase cathepsin D plays an im-
portant role in cell growth, proteolytic degradation, cell 
invasion and apoptosis (Beaujouin et al., 2006). Study 
in rats with streptozotocin-induced diabetes showed in-
creased proteolytic degradation of collagen in wounds 
(Pałka et al., 1991). This effect was reversed by exter-
nal application of a cathepsin D inhibitor, suggesting 
that this was the main enzyme responsible for collagen 
decomposition. Interestingly, patients with ulcerated dia-
betic foot had increased plasma levels of cathepsin D, 
which can contribute to poor wound healing (Ahmad et 
al., 2012).
CyToKInes InVolVeD In wounD HeAlIng
Cytokines are small proteins, soluble in the serum and 
interacting with cell surface receptors. They serve as a 
communication network between cells. By interaction 
with specific transmembrane receptor, they activate sig-
nal cascade, which result in cellular response (Nicholson 
et al., 2004).
Insuline-like growth factor (IGF) is a complex of 
two peptides: IGF-1 and IGF-2 (Jonathan et al., 2004). 
IGF-1 is a cytokine that participates in cell granulation 
during wound healing. During this process, expression 
of IGF-1 is increased. Interestingly, in diabetic patients 
expression of IGF-1 is decreased which may explain 
cell granulation defects (Yu et al., 2007; Blaktyny et al., 
2005). It was found that IGF-1 is crucial in the regu-
lation of the synthesis of Hif-1α protein during wound 
healing. The reduced level of IGF observed in diabe-
tes may explain low levels of Hif-1a protein (Yu et al., 
2007). Importantly, Hif-1α is an angiogenesis-promoting 
factor. It controls expression of several downstream fac-
tors involved in angiogenesis. Decreased levels of Hif-1α 
observed in diabetic mice and diabetic foot ulcers (Cat-
rina et al., 2004; Botusan et al., 2008) can be one of the 
major reasons of poor blood vessel formation in diabetic 
foot. IGF-2 plays a key role in the development of the 
embryo and fetus. Shao and colleagues (2008) found that 
in fetuses of mice with induced diabetes, IGF-2 mRNA 
levels were reduced almost by half comparing with con-
trols. It is possible that reduced level of IGF-2 is also 
associated with acute diabetes, since it is responsible for 
the development of pancreatic beta cells.
The process of wound healing in diabetic patients is 
also associated with a decreased level of expression of 
SDF-1α. Inhibition of SDF-1α activity leads to a reduc-
tion of the number of CD31+ cells which finally con-
tributes to the much slower wound repair (Bermudez et 
al., 2011). CD31 is one of the markers analyzed in an-
giogenesis. It is a glycoprotein present on the surface of 
endothelial cells, monocytes, granulocytes and platelets 
(Scelsi et al., 2005). SDF-1α activity is the most impor-
tant at early steps of wound healing, since its overex-
pression increases the healing rate (Badillo et al., 2007). 
Analysis of skin biopsies at the molecular level re-
veals pathogenic markers that are associated with delayed 
wound healing. These include primarily an increased 
level of c-Myc. Its expression is activated by β-catenin, 
which is involved in the inhibition of keratinocyte migra-
tion, and EGF response (Stojadinovic et al., 2005).
Recent studies indicate a relationship between mark-
ers of inflammation IL-6, IL-8, IGF-1 levels and mi-
crovascular changes in the same group of patients with 
type I diabetes. Studies show that the level of IGF-1 is 
decreased in respect to control group and this is linked 
with increased levels of IL-6 and IL-8 in young people 
with type I diabetes (Abo El Asrar et al., 2012).
A very important factor that affects the inflammatory 
response is micro RNA miR-146a. This small non-coding 
RNA serves as a negative feedback regulator of IRAK1 
and TRAF6 expression (Hou et al., 2009). IRAK1 and 
TRAF6 are elements of intracellular signal conducting 
cascade, and are associated with transmembrane recep-
tors, including RANKL/RANK (Gohda et al., 2005). It 
has been shown that the miR-146a expression is signifi-
cantly reduced in the wound in people diagnosed with 
diabetes. This correlates with an increased expression of 
its target genes IRAK1 and TRAF6, as well as related 
elements of the signaling cascade of NF-κB, IL-6 and 
MP-2 (Xu et al., 2012). This situation leads to enhanced 
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inflammatory response, and can be a reason for chronic 
inflammation related to diabetes. Interestingly, treatment 
of wounds with mesenchymal stem cells reduces inflam-
mation and accelerates wound healing. The treatment 
results in increased expression of miR-146a in the sur-
rounding tissue, thus expression of miR-146a may de-
pend on an extracellular signal (Xu et al., 2012).
fACToRs InVolVeD In fRACTuRe HeAlIng AnD 
bone RemoDelIng In DIAbeTes
The disease process in diabetic foot syndrome can 
lead to severe destruction of bone structures. The cause 
of these changes is not clear. Diabetes may cause a net 
loss of bone due to the strong suppression of bone for-
mation and accelerated bone resorption (Lu et al., 2003; 
Vestergaard et al., 2007). An increased bone-loss rate 
leads to development of osteopenia. It is characterized 
by the reduction of the mass of bone tissue, while re-
taining correct mineralization (Duarte et al., 2005).
It has been demonstrated that the molecular triad 
OPG/RANKL/RANK plays a major part in many 
bone-related diseases (Boyce et al., 2008). Osteoprote-
gerin (OPG) is a glycoprotein receptor from the fam-
ily of tumor necrosis factor (TNF) produced in many 
organs of the body, including osteoblasts (Loris et al., 
2001). It is present in a soluble form in the blood serum 
where its major role is capturing the excess of RANK 
ligand (RANKL). RANK protein is expressed in osteo-
clasts and their precursors. It is a membrane-anchored 
receptor present on the cell surface (Santini et al., 2011). 
RANKL is expressed mainly in bone and T cells, and 
plays an important role in the activation of osteoclasts 
(Santini et al., 2011; Boyce et al., 2008). RANKL bind-
ing to RANK receptor initiates a signal cascade mediated 
by TRAF6, leading to the activation and differentiation 
of the osteoclast which results in bone resorption. The 
effects of the interaction between RANKL and RANK 
are physiologically counterbalanced by OPG, which acts 
as a soluble receptor for RANKL and thus prevents the 
RANKL-RANK interaction. Any change in the ratio of 
RANKL to OPG may be critical in the control of the 
bone and skeletal system metabolism (Boyle et al., 2003).
It has been previously demonstrated in humans and in 
animal models that fracture healing in diabetes is much 
slower than in non-diabetic controls (de Amorin et al., 
2008; Duarte et al., 2007; Diniz et al., 2008; Vestergaard 
et al., 2005). De Amorin and collegues (2008) studied 
bone remodeling in rats with alloxan-induced diabetes. 
Their results showed that 14 days after fracture expres-
sion of RANK, RANKL and OPG was reduced at frac-
ture sites. However, the ratio of RANKL to OPG was 
clearly higher in the diabetic group, which may indicate 
increased bone resorption.
It was found that in rodents with type I diabetes the 
content of protein and minerals in the extracellular ma-
Table 1. molecular factors involved in diabetic foot syndrome formation
Factor Status in diabetes Effect Reference
PDGF decreased decreased upon fracture healing, possible defects in general wound healing Tyndal et al., 2003
KGF decreased healing rate decreased Werner et al.,1994
VEGF decreased healing rate decreased Frank et al., 1995,  Bitto et al., 2008
IL-6
increased enhanced immune response, sustained  inflammation state Abo El Asrar et al., 2012
IL-8
Igf-2 decreased decrease observed in diabetic mice fetuses, possible implications in pancreatic cell development Shao et al., 2008
Igf-1 decreased cell granulation defects Yu et al., 2007,  Blaktyny et al., 2005
mir-146 decreased enhanced immune response and sustained  inflammation state Xu et al., 2012
SDF1-α decreased slower healing rate, defects in angiogenesis Badillo et al., 2007,  Bermudez et al., 2011
c-Myc increased possible marker of B-catenin hyperactivation, resulting in inhibi-tion of keratinocyte migration and EGF response Stojadinovic et al., 2005
Hif1-α decreased possible defects in angiogenesis Catrina et al., 2004,  Botusan et al., 2008
RANKL increased disturbed RANKL/OPG ratio, possible increased bone resorption de Amorin et al., 2008
TNFα increased in wounds enhanced fibroblasts apoptosis Siqueira et al., 2010
TNFα
decreased in fractures increased osteoclast activation and bone resorption and cartila-ge removal
Kayal et al., 2007;  
Kayal et al., 2009TRAIL
MCF
cathepsin D increased abnormal collagen decomposition Ahmad et al., 2012
MMP-9 increased abnormal ECM decomposition, possible TGF1β degradation Ladwig et al., 2002;  Liu et al., 2009
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trix is reduced (Gandhi et al., 2006). It includes collagen, 
proteoglycan (PG), osteocalcin, calcium and magnesium. 
Additionally, the level of growth factors responsible for 
stimulating bone and cartilage formation IGF-1, PDGF, 
TGF-β1, basic fibroblast growth factor (bFGF), and 
VEGF is decreased. All these factors are essential for 
proper wound and bone healing, and their functional im-
pairment is common in diabetes in humans (Bennett et 
al., 2003, Blaktyny et al., 2009). 
Many factors that are specifically associated with os-
teoclast formation such as RANK, RANKL, tumor ne-
crosis factor α (TNFα), TNF-related apoptosis-inducing 
ligand (TRAIL) and macrophage colony-stimulating 
growth factor (M-CSF) are upregulated in diabetic mice. 
This correlates with increased number of osteoclasts in 
tissues, resulting in increased bone and cartilage removal 
(Kayal et al., 2007; Kayal et al., 2009).
In the past few years, several studies have suggested 
that OPG and RANKL are linked with Charcot arthropa-
thy (Jeffcoate, 2005; Mabilleau et al., 2008). It is a chronic 
disease characterized by progressive bone and joint de-
struction of the lower limbs. Symptoms are relatively pain-
less due to a loss of the sensory innervation. The most 
characteristic symptoms include pathological fractures, 
joint dislocation, and deformations (Rogers et al., 2011). 
The majority of patients with Charcot neuroarthropathy 
are between 50 and 60 years old, and most of them have 
been suffering from diabetes for at least 10 years (Rajb-
handari et al., 2002). A common feature of Charcot neu-
roarthropathy is increased bone reabsorption. It is most 
likely caused by increased activity of osteoclasts, which 
may lead to osteopenia (Pitocco et al., 2009). Additional 
evidence for a role of the molecular triad in Charcot neu-
roarthropathy development comes from genetic studies. It 
has been shown that selected polymorphisms in the opg 
gene occur more often in patients with diagnosed neu-
roarthropathy (Korzon-Burakowska et al., 2012).
Increased blood sugar levels in diabetics can lead 
to the formation of advanced glycation end products 
(AGEs) (Duarte et al., 2007), which are associated with 
delayed bone healing in these patients. Moreover, in dia-
betics this process may be escalated by the intensity of 
oxidative stress and the increased glucose levels (Santana 
et al., 2003). These conditions favor non-enzymatic glyca-
tion of proteins like hemoglobin, albumin, collagen and 
crystalline (Jabłońska-Trypuć, 2007). It is known that 
the accumulation of AGEs induces complicated changes 
in microdamage mechanism of bone (Tang et al., 2010) 
and leads to reduced mechanical strength of bone, which 
may cause fracture. 
ePIgeneTICs of THe DIAbeTIC fooT synDRome
Genetic mutations in factors directly involved in the 
diabetic foot syndrome are not solely responsible for 
the disease development. An increasing number of stud-
ies indicate the importance of epigenetic mechanisms in 
diabetes. Epigenetic changes are very diverse and include 
post-translational modifications of histones, methylation 
of cytosine in DNA, mitochondrial inheritance, micro-
RNA expression, as well as transposable elements (Slot-
kin & Martienssen, 2007; Goldberg et al., 2007; Kim et 
al., 2009). These changes affect gene expression without 
changes in genomic DNA sequence. DNA methylation as 
the basis of genetic imprinting is a process of inactivation 
of one gene allele, depending on the methylation pattern 
inherited from one of the parents. In consequence, only 
one copy of the gene is active. As an example, the IGF-
2 gene is expressed only from the paternal allele (DeChi-
ara et al., 1991). Large-scale studies of inherited methyla-
tion patterns and their association with disease identify 
several sites associated with type 2 diabetes (Kong et al., 
2009). Among these, the most relevant is the KCNQ1 
locus, which has been associated with mono- and poly-
genic diabetes in humans (Yasuda et al., 2008; Unoki et 
al., 2008). Interestingly, DNA methylation patterns can 
also change in response to environmental stimuli. The 
process is termed metabolic memory, and is defined by 
changes of genes expression in cells exposed to various 
stress conditions (Pirola et al., 2010). It has been shown 
that methylation of adiponectin gene in the placenta re-
sults in elevated protein levels in mother’s blood, and is 
inversely correlated with the mother’s blood sugar levels 
(Bouchard et al., 2012). It is known that hyperglycemia is 
the most important factor contributing to diabetes-related 
complications, as revealed by large-scale, long-term stud-
ies DCCT and EDIC (Diabetes Control and Complication 
Trial 1993) (Nathan et al., 2005; Pop-Busui et al., 2009). 
In addition to the human studies, there is a number of 
animal studies (Engerman et al., 1987; Hammes et al., 
1993; Kowluru et al., 2003) and in vitro cell culture studies 
(Roy et al., 1990; Ihnat et al., 2007) supporting the meta-
bolic memory hypothesis. Especially a study performed by 
El Osta and colleagues (2008) shows changes in histone 
methylation in the RELA promoter region induced by hy-
perglycemia and maintained after restoring non-glycemic 
conditions. This kind of epigenetic mechanism might con-
tribute to the overall picture of diabetic foot syndrome, 
changing expression of genes required for proper wound 
healing (Rafehi et al., 2012). However, despite numerous 
studies, there is no data about methylation patterns dur-
ing wound healing process, or relation with diabetic foot 
syndrome. There are, however, several examples of micro 
RNA-mediated changes in gene expression (Madhyastha et 
al., 2011; Caporali et al., 2011). Some information can be 
obtained from in vitro studies on vascular epithelial cells 
(Li et al., 2009). Indeed, performed experiments show in-
creased miR-221 RNA expression in HUVEC cells upon 
high glucose treatment. Treatment with miR-221 antisense 
RNA abolished the overexpression and restored the mi-
gration ability of the cells, which was previously impaired. 
However, the fact that epigenetic modifications can be in-
duced metabolically argues for animal model studies. An 
interesting model for an epigenetic mechanism involved 
in neuropathy development comes from a study on HIV-
associated-sensory neuropathy (HIV-SN) (Lehmann et al., 
2011). HIV-SN is among the most frequent complications 
of HIV infection. It is characterized by a progressive an-
aesthesia starting in the feet (Cornblath et al., 1988). Inter-
estingly, this neuropathy is caused by a deletion in the mi-
tochondrial genome, leading to mitochondrial dysfunction 
in distal axons. It is possible that the neuropathy related 
to diabetic foot has a similar etiology.
summARy
Diabetic foot syndrome is characterized by abnormali-
ties at the macroscopic, cellular and molecular level. In 
this article, we reviewed the most important issues con-
cerning cellular response and intracellular mechanisms 
affecting gene expression in the context of diabetic foot. 
The importance of the problem is highlighted by the in-
creasing number of detailed studies. Attempts to under-
stand the disease address different aspects of molecular 
biology, including the most recent findings about gene 
expression regulation. However, despite those extensive 
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studies in the field many questions remain unanswered. 
Future studies, although challenging, will bring more 
light into the field of diabetes-related complications, and 
most likely will result in effective therapies against dia-
betic foot syndrome.
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